Warfarin and aspirin in patients with heart failure and sinus rhythm

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F12%3A43899313" target="_blank" >RIV/00064173:_____/12:43899313 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023001:_____/12:00057976

Výsledek na webu

<a href="http://dx.doi.org/10.1056/NEJMoa1202299" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1202299</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1056/NEJMoa1202299" target="_blank" >10.1056/NEJMoa1202299</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Warfarin and aspirin in patients with heart failure and sinus rhythm

Popis výsledku v původním jazyce

It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm. RESULTS: The rates of the primary outcome were 7.47 events per 100 patient-years in the warfarin group and 7.93 in the aspirin group (hazard ratio with warfarin, 0.93; 95% confidence interval [CI], 0.79 to 1.10; P=0.40). Thus, there was no significant overall difference between the two treatments. In a time-varying analysis, the hazard ratio changed over time, slightly favoring warfarinover aspirin by the fourth year of follow-up, but this finding was only marginally significant (P=0.046). Warfarin, as compared with aspirin, was associated with a significant reduction in the rate of ischemic stroke throughout the follow-up period (0.72 events per 100 patient-years vs. 1.36 per 100 patient-years; hazard ratio, 0.52; 95% CI, 0.33 to 0.82; P=0.005). The rate of major hemorrhage was 1.78 events per 100 patient-years in the warfarin group as compared with 0.87 in the aspir

Název v anglickém jazyce

Warfarin and aspirin in patients with heart failure and sinus rhythm

Popis výsledku anglicky

It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm. RESULTS: The rates of the primary outcome were 7.47 events per 100 patient-years in the warfarin group and 7.93 in the aspirin group (hazard ratio with warfarin, 0.93; 95% confidence interval [CI], 0.79 to 1.10; P=0.40). Thus, there was no significant overall difference between the two treatments. In a time-varying analysis, the hazard ratio changed over time, slightly favoring warfarinover aspirin by the fourth year of follow-up, but this finding was only marginally significant (P=0.046). Warfarin, as compared with aspirin, was associated with a significant reduction in the rate of ischemic stroke throughout the follow-up period (0.72 events per 100 patient-years vs. 1.36 per 100 patient-years; hazard ratio, 0.52; 95% CI, 0.33 to 0.82; P=0.005). The rate of major hemorrhage was 1.78 events per 100 patient-years in the warfarin group as compared with 0.87 in the aspir

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

New England Journal of Medicine

ISSN

0028-4793

e-ISSN

—

Svazek periodika

366

Číslo periodika v rámci svazku

20

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

1859-1869

Kód UT WoS článku

000304083000005

EID výsledku v databázi Scopus

—